- Home
- SCPH vs PLRX Comparison
SCPH vs PLRX Comparison
Compare SCPH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- PLRX
- Stock Information
- Founded
- SCPH 2013
- PLRX 2015
- Country
- SCPH United States
- PLRX United States
- Employees
- SCPH N/A
- PLRX N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- PLRX Health Care
- Exchange
- SCPH Nasdaq
- PLRX Nasdaq
- Market Cap
- SCPH 173.6M
- PLRX 165.5M
- IPO Year
- SCPH 2017
- PLRX 2020
- Fundamental
- Price
- SCPH $2.78
- PLRX $1.47
- Analyst Decision
- SCPH Strong Buy
- PLRX Hold
- Analyst Count
- SCPH 3
- PLRX 10
- Target Price
- SCPH $14.00
- PLRX $9.79
- AVG Volume (30 Days)
- SCPH 629.3K
- PLRX 3.4M
- Earning Date
- SCPH 03-19-2025
- PLRX 03-03-2025
- Dividend Yield
- SCPH N/A
- PLRX N/A
- EPS Growth
- SCPH N/A
- PLRX N/A
- EPS
- SCPH N/A
- PLRX N/A
- Revenue
- SCPH $36,332,000.00
- PLRX N/A
- Revenue This Year
- SCPH $134.20
- PLRX N/A
- Revenue Next Year
- SCPH $99.40
- PLRX $46.66
- P/E Ratio
- SCPH N/A
- PLRX N/A
- Revenue Growth
- SCPH 167.28
- PLRX N/A
- 52 Week Low
- SCPH $2.72
- PLRX $1.26
- 52 Week High
- SCPH $5.65
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- SCPH 34.45
- PLRX 26.84
- Support Level
- SCPH $2.87
- PLRX $1.42
- Resistance Level
- SCPH $3.08
- PLRX $1.78
- Average True Range (ATR)
- SCPH 0.18
- PLRX 0.13
- MACD
- SCPH -0.00
- PLRX 0.26
- Stochastic Oscillator
- SCPH 11.70
- PLRX 14.08
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.